Literature DB >> 15213849

Platelet inhibition by aspirin is diminished in patients during carotid surgery: a form of transient aspirin resistance?

David A Payne1, Chris I Jones, Paul D Hayes, Sally E Webster, A Ross Naylor, Alison H Goodall.   

Abstract

The majority of patients who suffer peri-operative thromboembolic complication while undergoing vascular procedures do so despite taking aspirin. This study examined the antiplatelet effect of aspirin during surgery in patients undergoing carotid endarterectomy (CEA). Fifty patients undergoing CEA were standardised to 150 mg aspirin daily for > or =2 weeks. Platelet aggregation in response to arachidonic acid (AA) was measured in platelet rich plasma prepared from blood taken prior to, during, and at the end of surgery. Spontaneous platelet aggregation was also studied, as was the role of physiological agonists (ADP, collagen, thrombin, and epinephrine) in mediating the in vivo and in vitro responses to AA. Eighteen patients undergoing leg angioplasty, also on 150 mg aspirin, without general anaesthesia, served as a control group. In the CEA patients aggregation induced by AA (5 mM) increased significantly from 7.6 +/- 5.5% pre-surgery to 50.8 +/- 29.5% at the end of surgery (p <0.0001). Aggregation to AA was even greater in samples taken mid-surgery from a sub-set of patients (73.8+/-7.2%; p = 0.0001), but fell to 45.9 +/- 7.4% by the end of surgery. The increased aggregation in response to AA was not due to intra-operative release of physiological platelet agonists since addition of agents that block/neutralise the effects of ADP (apyrase; 4 micro g/ml), thrombin (hirudin; 10 units/ml), or epinephrine (yohimbine; 10 micro M/l) to the samples taken at the end of surgery did not block the increased aggregation. The patients undergoing angioplasty also showed a significant rise in the response to AA (5 mM), from 5.6 +/- 5.5% pre-angioplasty to 32.4 +/- 24.9% at the end of the procedure (p <0.0001), which fell significantly to 11.0 +/- 8.1% 4 hours later. The antiplatelet activity of aspirin, mediated by blockade of platelet arachidonic acid metabolism, diminished significantly during surgery, but was partially restored by the end of the procedure without additional aspirin treatment. This rapidly inducible and transient effect may explain why some patients undergoing cardiovascular surgery remain at risk of peri-operative stroke and myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15213849     DOI: 10.1160/TH03-12-0758

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  Aspirin resistance in off-pump coronary artery bypass grafting.

Authors:  Zanxin Wang; Fei Gao; Jianlong Men; Jing Ren; Paul Modi; Minxin Wei
Journal:  Eur J Cardiothorac Surg       Date:  2012-01       Impact factor: 4.191

2.  [Prevalence of acetylsalicylic acid (ASA) - low response in vascular surgery].

Authors:  T Hummel; S H Meves; K Rüdiger; A Mügge; A Mumme; B Burkert; D Mühlberger; H Neubauer
Journal:  Chirurg       Date:  2016-05       Impact factor: 0.955

3.  Aspirin resistance: a clinical review focused on the most common cause, noncompliance.

Authors:  Kenneth A Schwartz
Journal:  Neurohospitalist       Date:  2011-04

4.  Perioperative changes of response to antiplatelet medication in vascular surgery patients.

Authors:  Thomas Hummel; Saskia Hannah Meves; Andreas Breuer-Kaiser; Jan-Ole Düsterwald; Dominic Mühlberger; Achim Mumme; Horst Neubauer
Journal:  PLoS One       Date:  2020-12-29       Impact factor: 3.240

5.  'Aspirin resistance' or treatment non-compliance: which is to blame for cardiovascular complications?

Authors:  Eduard Shantsila; Gregory Y H Lip
Journal:  J Transl Med       Date:  2008-08-29       Impact factor: 5.531

6.  The Pre- and Postoperative Prevalence and Risk Factors of ASA Nonresponse in Vascular Surgery.

Authors:  Alia Uzra Kazimi; Christian Friedrich Weber; Michael Keese; Wolfgang Miesbach
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.